2653-16-9Relevant articles and documents
Indolone derivative and pharmaceutical application thereof
-
Paragraph 0040-0044; 0057-0058, (2021/03/31)
The invention provides an indolone derivative and pharmaceutical application thereof. The structure of the indolone derivative is shown as a formula (A). Experimental results show that the compound provided by the invention has obviously improved pharmacokinetic properties than BIBF1120, has excellent inhibition effects on VEGFR, FGFR and PDGFR, can be used as a VEGFR, FGFR and/or PDGFR inhibitor,an angiogenesis inhibitor and a drug for preventing and/or treating various tumors including pharyngeal squamous cell carcinoma, and has a wide application prospect.
Novel synthesis method of nilotinib intermediate 2-chloro -N- methyl -N-(4- nitrophenyl) acetamide (by machine translation)
-
Paragraph 0027-0029, (2020/04/22)
The method sequentially comprises the following steps, generating chlorine - 2 - N N-methyl -) N N N N. N (methyl - N N N N N- methyl-N,(N-)-nitrophenyl 2 - acetamide) in, a brand-new synthetic route in a brand-new synthesis route. 2 - The present invention, provides a) brand-new synthesis, route of compound chloride - N, N-methyl-N-(N-N-(N-(, N-(N, N,(N-(N-N-(N-(N-N-(N-(N-(N-N-(N-(N-N-(N. (by machine translation)
Method for preparing Nintedanib,I intermediate through one-pot method
-
Paragraph 0026; 0027; 0028; 0030; 0032; 0034; 0036; 0040, (2018/10/19)
The invention relates to a method for preparing Nintedanib,I key intermediate N-(4-aminophenyl)-N-methyl-2-(4-methyl piperazine-1-group)acetamide through a one-pot method. The method comprises the steps that according to the technical scheme, N-methyl-4-nitroaniline is dissolved in an aqueous solution of an organic solvent and alkali, mixing is carried out, then chloroacetyl chloride or bromoacetyl bromide is dropwise added, and a first-stage reaction is carried out for 0.1-3 hours at the temperature of 0-70 DEG C; a water layer is removed, N-methyl piperazine is added, a second-stage reactionis carried out, and reacting is carried out for 2-10 hours at the temperature of 0-75 DEG C; then a reducing reagent is added, a third-stage reaction is carried out for 8-36 hours at the temperatureof 0-75 DEG C and the pressure of 15-100 psi. After the reaction is finished, filtering is carried out to remove the reducing reagent, the reaction liquid is condensed, a reverse phase solvent is added, crystallization is carried out, and the Nintedanib,I key intermediate N-(4-aminophenyl)-N-methyl-2-(4-methyl piperazine-1-group)acetamide (formula B) is obtained. According to the preparation method, the raw materials are easy to obtain, the process is simple, and the method is economical, environmentally friendly and suitable for industrial production.